Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron DeficiencyStatus: open
17-247 - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
Treatment for Heart Failure with Iron deficiency
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction.
SponsorsThis trial is sponsored by Luitpold Pharmaceuticals.
Interested in Clinical Trial?
Providers Associated With This Trial
- Christopher M. Malozzi, D.O.CardiologistAssistant Professor of Internal Medicine
- Bassam A. Omar, M.D., Ph.D., F.A.C.C.CardiologistFellowship Director of Cardiovascular Diseases; Professor of Internal Medicine
- Michael V. Cohen, M.D.CardiologistProfessor of Physiology and Cell Biology
- Ghulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine